radicicol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: radicicol
• 英文别名: monorden；RDC；(4R,6S,8S,9Z,11E)-16-chloro-17,19-dihydroxy-4-methyl-3,7-dioxatricyclo[13.4.0.06,8]nonadeca-1(15),9,11,16,18-pentaene-2,13-dione
• 化学式: C₁₈H₁₇ClO₆
• 分子量: 364.782
• InChiKey: WYZWZEOGROVVHK-RPJJWQTDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  25
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  96.4
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  radicicol 在 cerium(III) chloride 、 sodium tetrahydroborate 、 disodium hydrogenphosphate 、 水 作用下， 以 甲醇 、 水 为溶剂， 反应 0.67h， 生成 (4R,6S,8S,9Z,11E,13R)-16-chloro-13,17,19-trihydroxy-4-methyl-3,7-dioxatricyclo[13.4.0.06,8]nonadeca-1(15),9,11,16,18-pentaen-2-one
  参考文献：
  名称：

  EP1498104

  摘要：

  公开号：

文献信息

• [EN] GRP94 INHIBITORS<br/>[FR] INHIBITEURS DE GRP94
  申请人：UNIV KANSAS

  公开号：WO2012139010A1

  公开（公告）日：2012-10-11

  The present disclosure provides a series of compounds which exhibit isoform selective inhibition of GRP94, a homologue of Hsp90 that is localized to the endoplasmic recticulum. Through GRP94 inhibition, these compounds are likely to manifest anti-cancer, anti-inflammatory, anti-metastasis, and immunosuppressive activities, as well as utility in the treatment of neurodegenerative diseases, and diabetes.

  本公开提供了一系列化合物，这些化合物表现出对GRP94的异构选择性抑制作用，GRP94是定位于内质网的Hsp90同源物。通过抑制GRP94，这些化合物有可能表现出抗癌、抗炎、抗转移、免疫抑制和在治疗神经退行性疾病和糖尿病方面的用途。
• Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
  申请人：Kasibhatla R. Srinivas

  公开号：US20070129334A1

  公开（公告）日：2007-06-07

  Novel purine compounds and tautomers and pharmaceutically acceptable salts thereof are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same. Methods of using the novel purine compounds of the invention, and tautomers and pharmaceutically acceptable salts thereof, include their use in inhibiting heat shock protein 90's (HSP90's) to thereby treat or prevent HSP90-dependent diseases, e.g., proliferative disorders such as breast cancer.

  本发明描述了新型嘌呤化合物及其互变异构体和药学上可接受的盐，以及包含它们的制药组合物、包含它们的复合物（例如HSP90复合物）和使用它们的方法。使用本发明的新型嘌呤化合物、互变异构体和药学上可接受的盐的方法包括在抑制热休克蛋白90（HSP90）中使用它们，从而治疗或预防HSP90依赖性疾病，例如增生性疾病如乳腺癌。
• Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
  申请人：Zhang Hong

  公开号：US20070105874A1

  公开（公告）日：2007-05-10

  The present invention provides a method of treating an individual having an HSP90 mediated disorder comprising administering to said individual a pharmaceutical composition comprising a pharmaceutically effective amount of a synthetic heterocyclic HSP90 inhibitor, wherein the activity of the HSP90 inhibitor is substantially independent of multi drug resistance. In one embodiment, the activity of the HSP90 inhibitor is substantially independent of P-gp and MRP expression.
• GRP94 INHIBITORS
  申请人：Blagg Brian S.J.

  公开号：US20130109684A1

  公开（公告）日：2013-05-02

  The present disclosure provides a series of compounds which exhibit isoform selective inhibition of GRP94, a homologue of Hsp90 that is localized to the endoplasmic recticulum. Through GRP94 inhibition, these compounds are likely to manifest anti-cancer, anti-inflammatory, anti-metastasis, and immunosuppressive activities, as well as utility in the treatment of neurodegenerative diseases, and diabetes.
• EP1498104
  申请人：——

  公开号：——

  公开（公告）日：——